Thursday, Sep. 24, 2020

An Atlantic Cardiovascular Medicine Update for Family Medicine, Emergency Physicians and those interested in CVD Care.



Time	Торіс	Faculty
1:00 - 1:10 pm	Introductions / Objectives / Instructions	Dr. Paul MacDonald
1:10 - 1:30 pm	Management of non-ST-elevation/acute coronary syndrome in the Emergency Room and at discharge from hospital. What medication is necessary and is colchicine treatment for everyone? Learning Objective: At the completion of this session participants will be able to better apply the body of clinical evidence for medication use when managing patients diagnosed with NSTEMI/ACS in the Emergency Department.	Dr. Iqbal Bata QEII Health Sciences Halifax, NS
1:30 - 1:45 pm	Participant Question Period	
1:45 - 2:05 pm	Assessment of challenging STEMI cases and which cardiac patients require emergency transfer. How is Drip and Ship working so far. Learning Objective: At the completion of this session participants will be able to more effectively classify which STEMI patients require an emergent catheterization lab transfer.	Dr. Sohrab Lutchmedial NB Heart Centre Saint John, NB
2:05 - 2:20 pm	Participant Question Period	
2:20 - 2:40 pm	Assessment of low-risk chest pain in the Emergency Department. Heart score, biomarkers, and other considerations in assessment. Who needs a cardiology referral and who needs a cardiac stress test. Learning Objective: At the completion of this session participants will be able to define which assessment tools can more accurately establish which patients with low-risk chest pain require a cardiac stress test.	Dr. David Bewick NB Heart Centre Saint John, NB
2:40 - 2:55 pm	Participant Question Period	
2:55 - 3:10 pm	Refreshment Break	
3:10 - 3:30 pm	Diabetes and cardiovascular drugs. The SGLT2 inhibitors seem useful with or without diabetes. How should these medications be properly used and which drugs for which patient. Learning Objective: At the completion of this session participants will be able to define which cardiac patients will derive maximal clinical benefit from the SGLT2 class of medications.	Dr. Kim Anderson QEII Health Sciences Halifax, NS
3:30 - 3:45 pm	Participant Question Period	

3:45 - 4:05 pm	Congestive heart failure update including treatments for preserved ejection fraction. Are new drugs worth the cost and what is needed to obtain provincial coverage (Entresto, Ivabradine and Carvedilol). Learning Objective: At the completion of this session participants will be able to critically appraise the body of clinical evidence for medications used in the management of congestive heart failure.	Dr. Andrew Moeller QEII Health Sciences Halifax, NS
4:05 - 4:20 pm	Participant Question Period	
4:20 - 4:30 pm	Meeting Debrief / Evaluation	



This one-credit-per-hour Group Learning program meets the certification criteria of the College of Family Physicians of Canada and has been certified by the Continuing Professional Development Office of Dalhousie University or up to 3.0 Mainpro+ credits.

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by Continuing Professional Development, Dalhousie University. You may claim a maximum of 3.0 hours (credits are automatically calculated).

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 CreditsTM. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.amaassn.org/go/internationalcme.

